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Abstract
It is commonly claimed that the nausea and vomiting accompanying cytotoxic chemotherapy have
a negative impact on health-related quality of life. While this may seem self-evident, until a few years
ago there was little empirical data demonstrating that the failure to control postchemotherapy
emesis affects aspects of quality of life.
In spite of their limitations, several observational studies showed that nausea and vomiting
associated with chemotherapy induced a decrease in health-related quality of life with respect to
patients without nausea and vomiting. This has also been demonstrated after the adjustment for
health-related quality of life before chemotherapy that is an important prognostic factor of
chemotherapy-induced nausea and vomiting.
Furthermore, one study suggests that the optimal time of assessment of quality of life to evaluate
the impact of chemotherapy-induced nausea and vomiting is day 4 if a 3-day recall period is used
or day 8 when the recall period is 7 days.
In double-blind studies the efficacy, tolerability and impact on quality of life of the 5-HT3 receptor
antagonists was superior with respect to metoclopramide, alizapride and prochlorperazine. Similar
results have been achieved with the combination of ondansetron with dexamethasone, the
standard treatment for the prevention of acute emesis induced by moderately emetogenic
chemotherapy, with respect to the metoclopramide plus dexamethasone combination. Instead, in
another double-blind study, in patients submitted to moderately emetogenic chemotherapy, a 5-
HT3 antagonist did not seem to significantly increase complete protection from delayed emesis and
the patients' quality of life with respect to dexamethasone alone. In conclusion, the evaluation of
quality of life in randomized trials comparing different antiemetic drugs for the prevention of
chemotherapy-induced nausea and vomiting can add important information useful for the choice of
the optimal antiemetic treatment.
Introduction
About 20 years ago vomiting and nausea ranked as the
most distressing side effects of cancer chemotherapy from
the patients' point of view [1]. Unfortunately, despite
progress achieved with the 5HT3  receptor antagonists
chemotherapy-induced nausea and vomiting remains a
distressing adverse event. In fact, in two studies carried out
after their introduction in clinical practice, nausea still
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ranks number 1 as the adverse event of chemotherapy of
most concern to patients, with vomiting ranking as the 3rd
and the 5th most distressing symptom [2,3].
This is probably due to the unsatisfactory efficacy of the
available antiemetic drugs to prevent delayed emesis, a
phenomenon which has been arbitrarily defined as vom-
iting and/or nausea beginning, or persisting for, more
than 24 hours after chemotherapy administration [4].
Another reason is that often the results of clinical research
are not transferred to clinical practice [5].
Clinical consequences of chemotherapy-induced emesis
(CIE) include oesophageal tear, fractures, malnutrition,
acid-base and electrolyte changes and patients' refusal to
continue chemotherapeutic cycles, thus decreasing
health-related quality of life (HRQL) and compromising
treatment efficacy [6].
In this paper we analyse the impact of CIE on HRQL. A
search of published articles in English language in the
MEDLINE electronic bibliographic databases from 1976
to 2002 was carried out.
Abstracts were considered relevant if the article: 1)
described the development and validation of an HRQL
instrument used to assess HRQL in CIE; 2) described the
impact of CIE on HRQL; 3) compared HRQL between dif-
ferent antiemetic drugs for the prevention of CIE. The
electronic search was supplemented by a manual review
of the bibliographies of the references retrieved.
Chemotherapy-induced emesis and health-related quality 
of life
It is commonly claimed that the nausea and vomiting
accompanying cytotoxic chemotherapy have a negative
impact on HRQL. While this may seem self-evident, there
is little empirical data demonstrating that the failure to
control postchemotherapy emesis affects aspects of qual-
ity of life other than directly related physical symptoms
[6]. In fact, until 1992 studies that considered the impact
of nausea and vomiting on a broader, multidimensional
measure of quality of life were lacking. Furthermore, one
study carried out in breast cancer patients showed that the
important determinants of a good quality of life for them
appear to be their ability to complete the activities of eve-
ryday living and their emotional well-being, while nausea
and vomiting, when present, were not powerful inde-
pendent predictors of variations in overall quality of life
[7]. A possible criticism of this study is that most of these
patients had not recently received chemotherapy and had
no experience of nausea and vomiting. On the other hand,
improvement in the control of nausea and vomiting lead
to a smaller decrease in the quality of life of cancer
patients in the few days following chemotherapy, but
other issues can be more important determinants of qual-
ity of life in the long term.
However, it was less clear precisely how important nausea
and vomiting may be and to what extent their effects are
independent of the other toxicities of chemotherapy and
indeed of the effects of the diagnosis and disease itself [7].
Some studies have tried to answer to these questions
(Table 1).
Studies without comparative purpose
Lindley et al. evaluated 122 patients with various cancers
submitted to different emetogenic chemotherapies and
different antiemetic prophylaxis [8]. Emesis (one or more
episodes of vomiting and/or a nausea severity of 2.0 cm or
more on a 10 cm visual analogue scale) was reported by
56% of patients. To evaluate emesis and its impact on
quality of life three instruments were used before chemo-
therapy and 3 days after: a diary card where the number of
vomiting and retching episodes occurring every day was
recorded as well the severity of nausea, sedation and anx-
iety experienced by the patients; the Functional Living
Index – Cancer (FLIC) a validated instrument to assess the
patient's quality of life [9]; the Functional Living Index –
Emesis (FLIE), an instrument created, pre-tested and
revised prior the study, with questions modelled after
those of the FLIC but specifically addressing the impact of
chemotherapy induced nausea and vomiting on the phys-
ical activities, social and emotional function and ability to
enjoy meals. The score of the FLIC (FLIE) was determined
by summing the responses to the 22 (18) questions on a
7 point analogue scale and, therefore, the range of total
scores possible is between 22 (18), all 1 responses on each
scale, and 154 (126), all 7 responses on each scale. A
higher score corresponds to a higher quality of life (less
negative impact on the patient's functional living by nau-
sea and vomiting).
The mean quality of life score for patients of the FLIC
decreased significantly from 121 before to 110 three days
after chemotherapy, but it was statistically significant only
in those patients experiencing emesis (from 119 to 101)
while in those not reporting emesis the score was not dif-
ferent following chemotherapy (from 124 to 122). Simi-
lar results were obtained with the FLIE: the mean score
decreased from 118 before to 101 three days after chemo-
therapy, but the decrease was dramatic in patients who
experienced emesis (from 115 to 85) as compared to a
constant level for the non-emesis patient group. Chemo-
therapy and antiemetic therapy seem to contribute signif-
icantly to changes in quality of life observed. In fact, of
patients who experienced chemotherapy-induced emesis,
23% were unable to go to work due to emesis, 22%
reported they were unable to prepare meals due to emesis;
12% reported that emesis made them unable to care forHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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themselves; 12% reported that they were unable to take
prescribed medications on at least two occasions due to
emesis.
In another study, 109 patients that had previously experi-
enced nausea and vomiting and/or side effects with the
use of standard antiemetic agents were submitted in the
following cycle of a similar chemotherapy regimen to a
compassionate-use program of ondansetron (0.15 mg/kg
i.v. every 4 hours for three daily doses) [10]. Two assess-
ment tools were used to evaluate patient's conditions: a
score ranging from 1 to 10 for physician's assessment and
the FLIE questionnaire filled out by the patient. In this
case the score for the 18 items of FLIE was added and
transposed to a 100-point scale to give a final score, with
a higher score indicating a better quality of life. The mean
score was significantly better with ondansetron than with
standard antiemetics (65.5 versus 39.5). The FLIE scores
were higher for 76% of patients during ondansetron treat-
ment as compared to previous chemotherapy with stand-
ard antiemetics. Possible criticisms are that (i) the
difference in scores is probably overestimated because of
the time of assessment (both after treatment with
ondansetron), and (ii) the shortcomings in the study
design (neither randomised, nor double-blind).
One study evaluated the effect of chemotherapy-induced
nausea and vomiting on health-related quality of life
before the 5-HT3 antagonists became available [11]. In 92
patients submitted to moderately and highly emetogenic
chemotherapy the incidence of nausea and vomiting for 5
consecutive days and their impact on quality of life was
evaluated. Quality of life was assessed by the FLIE that was
completed before chemotherapy, and on day 2 and 5
after. The summed scores were standardized to a 100
point-scale. Over the 5 days of the survey 72 patients
(78%) reported nausea or at least one emetic episode. The
FLIE scores indicated significant worsening of functional
status associated with chemotherapy, but an improve-
ment after the first 24 hours following chemotherapy, an
improvement that was greater for emesis than for nausea.
On day 2 the main impact was from emesis, particularly
with regard to leisure activities, household tasks and hard-
ship on the family. On the other hand, nausea had a sig-
nificantly greater impact than emesis on overall
functioning, enjoyment of eating and hardship on the
patient.
Two studies have been published by the Quality of Life
and Symptom Control Committees of the National Can-
cer Institute of Canada Clinical Trials Group assessing
whether prechemotherapy HRQL variables were associ-
ated with postchemotherapy nausea and vomiting and
their relationship to patient and treatment variables [12]
and the effect of postchemotherapy nausea and vomiting
on HRQL [13] in 802 patients submitted to moderately
and highly emetogenic chemotherapy. The HRQL used
the questionnaire of the European Organization for
Research and Treatment of Cancer (EORTC) Core Quality
of Life Questionnaire (QLQ-C30) [14] completed by the
patient from 0 to 7 days before chemotherapy (baseline)
and at home 7 days after the chemotherapy (day 8) for
both studies and on the first day of the second cycle of
chemotherapy (day 15–29), for the second study.
The EORTC QLQ-C30 is a 30-item self-report question-
naire that contains questions exploring five functioning
domains (physical, role, emotional, cognitive and social),
an overall or "global" quality of life domain, three symp-
tom domains (pain, fatigue, nausea/vomiting) and six
single items (dyspnoea, insomnia, anorexia, diarrhoea,
constipation, and financial difficulties). The raw scores for
Table 1: Studies without comparative purpose
Author [ref.] Pts (no.) Cancer (type) Chemotherapy 
(emetogenicity)
Antiemetics HRQL assessment (times) Selection of pts
Lindley [8] 122 various various various FLIC and FLIE (before and 
after 3 days)
162 pts eligible, 140 agreed to 
participate, 122 evaluated HRQL
Berry [10] 109 various various OND use 
compassionate
FLIE (n.s.) 350 pts, 190 received similar CT, 
109 evaluated HRQL
O'Brien [11] 92 various Moderately and highly DEX + MTC or PCP 
± other
FLIE (before and after 2 
and 5 days)
128 pts eligible, 112 agreed to 
participate, 107 evaluated HRQL (15 
pts excluded for multiple days CT)
Osoba [12] 802 various Moderately and highly 5-HT3 ± DEX EORTC QLQ-C30 (before 
and after 7 days)
Osoba [13] 802 various Moderately and highly 5-HT3 ± DEX EORTC QLQ-C30 (before 
and after 7 days)
Possible selection bias at HRQL 
evaluated before 2nd cycle CT (70% 
of pts)
Rusthoven 
[16]
119 various Moderately Standard for Centers EORTC QLQ-C30 (before 
and after 2 and 6 days)
124 pts eligible, 119 evaluated 
HRQL
CT: chemotherapy, DEX: dexamethasone, HRQL: Health-related quality of life, OND: ondansetron, PCP: prochlorperazine, 5-HT3: 5-HT3 
antagonist, n.s.: not specified.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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each domain and single item are transformed to give a
score lying between 0 and 100. For the functioning
domains and global quality of life, a higher score indicates
a better or higher level of functioning; for the symptom
domains and single items, a higher score indicates a
greater level of symptoms or problems. The patients filled
out a diary card for the assessment of nausea and
vomiting.
In the first study [12] patients were divided into two
groups: those who did not report nausea or vomiting and
those who had nausea and one or more emetic episodes
in the week after chemotherapy administration. More
than 98% of patients completed the baseline question-
naire. Nausea was reported by 75.6% and vomiting by
55.7% of patients during the study period.
At the univariate analysis, the mean pretreatment scores in
patients who suffered from chemotherapy-induced nau-
sea were significantly lower for physical, role, emotional,
cognitive, and social functioning than in patients without
nausea. Patients with nausea also had significantly higher
fatigue, preexisting nausea, pain, insomnia, constipation,
financial difficulties and daytime drowsiness scores.
Patients who vomited after chemotherapy had signifi-
cantly worse physical, role and social functioning, and
global quality of life scores before chemotherapy than
patients who did not vomit. Furthermore, patients who
vomited had significantly higher fatigue, preexisting nau-
sea, pain, anorexia, constipation, financial difficulties,
and daytime drowsiness scores before chemotherapy than
those who did not suffer from vomiting.
On the other hand, pretreatment quality of life scores
were not found significantly correlated with the intensity
of postchemotherapy vomiting (1–2 episodes versus
more than 2 episodes).
Five patient characteristics were positively associated with
postchemotherapy nausea (females, history of motion
sickness, drowsiness and prechemotherapy nausea) and
two with postchemotherapy vomiting (ECOG perform-
ance status of 1 and 2 and consumption of 10 or less alco-
holic drinks per week).
At the multivariate analysis, the variables remaining in the
final model included low social functioning, prechemo-
therapy nausea, female gender, highly emetogenic chem-
otherapy and the lack of maintenance antiemetics after
chemotherapy. A history of low alcohol intake was also
associated with postchemotherapy vomiting while
increased fatigue and lower performance status were asso-
ciated with postchemothrepay nausea.
The risk of postchemotherapy vomiting increased from
20% in patients having no risk factors to 76% in those
having any four of a total of six risk factors.
The predictive value of certain health-related quality of
life domains for postchemotherapy vomiting showed in
this study and not in the previous studies can be related to
the different scoring systems of the EORTC and FLIC-FLIE
questionnaires. In fact, the scoring of FLIC and FLIE ques-
tionnaires provides a single aggregate score as a measure
of HRQL, whereas the scoring of the EORTC question-
naire provides separate scores for each domain and symp-
tom. A single, aggregate score encompasses many
domains and if only some of them have predictive value
then those domains that do not have predictive value will
mask the domains that do have predictive value. The
result will be a dilution of the aggregate score that then, of
itself, will not be predictive. This strongly supports the
view that multidimensional instruments should be scored
and analysed for the information provided by each of the
separate domains. On the other hand, it is necessary to
remember that the Canadian study is that with the largest
number of patients enrolled and that the non-predictive
value of HRQL scores of the previous studies could be due
to the low number of patients evaluated.
In the second study [13] the patients were divided in four
groups: those who experienced both nausea and vomit-
ing, those with nausea without emetic episodes, those
with no nausea but with vomiting, and those with neither
nausea nor vomiting. To evaluate the impact of
postchemotherapy nausea and vomiting on HRQL the
change in scores between the baseline and day 8 after
chemotherapy administration was calculated for each
domain and symptom of the questionnaire and compared
in the four subgroups of patients. On day 8, 94.8% of
patients filled out the questionnaire while about 70%
completed it on the day of their second cycle of
chemotherapy.
On day 8 the group with both nausea and vomiting
showed statistically significant worse physical, cognitive
and social functioning, global quality of life, fatigue, ano-
rexia, insomnia and dyspnea as compared to the group
with neither nausea nor vomiting. Patients with only nau-
sea but no vomiting tended to have less worsening in
functioning and symptoms than those having both nau-
sea and vomiting.
Increased severity of vomiting (> 2 episodes) was associ-
ated with worsening only of global quality of life and ano-
rexia compared with 1–2 episodes of vomiting.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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After 2–4 weeks from the chemotherapy all quality of life
scores either returned to their baseline levels or were bet-
ter than baseline.
In this study the effect of chemotherapy-induced emesis
on HRQL was evaluated taking into account the prechem-
otherapy health-related quality of life status. In fact, the
authors first subtracted the baseline scores from the day 8
scores and then used the difference to compare the sub-
groups of patients with and without postchemotherapy
nausea and vomiting. In this way the non-emetogenic
effects of chemotherapy on postchemotherapy quality of
life could also be considered at least in part; in fact, com-
paring the differences in changed scores between patients
who vomited, it was assumed that the effects of chemo-
therapy or other variables were likely to be similar in the
two groups because of the large sample size.
Finally, another possible explanation for the apparently
different results of these two studies with respect to the
previous ones is that postchemotherapy quality of life was
assessed 7 days after chemotherapy administration
instead of 4 or 2 days.
The importance of the time of administration and of the
time frame of quality of life assessment was evaluated in
another Canadian study carried out in 650 patients sub-
mitted to moderately emetogenic chemotherapy [15]. The
initial observation suggesting the necessity of this study
was: despite the fact that patients who experienced greater
nausea and vomiting reported a significantly worse qual-
ity of life, when quality of life was compared across treat-
ment arms, which differed substantially in the control of
emesis, no statistically significant difference in any quality
of life outcome measures was found. The most likely
explanation of this is that, as emesis is more intense in the
first 2–3 days after chemotherapy, administering a ques-
tionnaire on day 8 (time frame: 7 days) could lead to
attenuating the perceived effects of emesis on their HRQL.
In this study the participating centres were randomized to
one of four quality of life assessment procedures. Patients
in all centres completed a baseline questionnaire within
72 hours prior to study entry and a post-treatment assess-
ment on either day 4 or 8 after chemotherapy. The selec-
tion of day 4 or 8 was randomized by centre. The time
frames of the questionnaires were also randomly varied
by centre to be either 7 days, as in the standard instru-
ment, or 3 days, as a modified version.
When the quality of life questionnaire is administered on
day 8, the changes in global quality of life are significantly
greater when the recall period is 7 days than when it is 3
days (- 10.3 versus -1.2, P < 0.01) and when a 3 day recall
period is used the changes are significantly greater when
the questionnaire is administered on day 4 than on day 8
(-8.4 versus -1.2, P < 0.001). Furthermore, in this study
the addition of dexamethasone to a 5-HT3 antagonist sig-
nificantly improved the control of emesis over the entire
study period with respect to a 5-HT3 antagonist alone.
These results were parallel to those achieved on quality of
life scores; in fact, patients receiving dexamethasone fared
significantly better with respect to global quality of life,
physical functioning and social functioning and symptom
scales. Administering the questionnaire at the time of
greatest symptoms, i.e. 3 days after chemotherapy, is the
most sensitive means of detecting a treatment difference.
In another Canadian study, patients submitted to moder-
ately emetogenic chemotherapy were monitored for nau-
sea and vomiting and a modified version of the EORTC
QLQC-30 questionnaire was administered before chemo-
therapy and on day 2 and day 6 to assess the impact nau-
sea and vomiting had on quality of life of the patients
[16].
Patients who experienced either nausea or vomiting had a
decrease in quality of life from prechemotherapy levels on
six functioning and five symptoms scale at day 2 and on
four functioning and four symptom scales on day 6. Com-
parison of mean scores between the unmodified EORTC
QLQC-30 and the nausea and vomiting versions demon-
strated that the HRQL rating attributed to nausea and
vomiting accounted for much, but not all, of the deterio-
ration in HRQL scores in patients who experienced these
symptoms. Therefore, other reasons for some of the
decrease in health-related quality of life must be identified
in future studies.
In conclusion, although observational studies present
many risks of confounding bias, it seems that at least in
part the CIE induced a decrease of HRQL. This has been
also demonstrated after the adjustment for HRQL before
chemotherapy that is an important prognostic factor of
CIE. Finally, observational studies showed the importance
of the time of administration and of the time frame of
quality of life assessment. The possibility to identify the
impact of CIE on HRQL is significantly greater when the
questionnaire is administered on day 4 than on day 8, if a
3-day recall period is used, or when the questionnaire is
administered on day 8, but the recall period is 7 days
instead of 3 days.
Studies comparing the impact of different antimetics on 
HRQL
Table 2 summarizes the comparative studies among dif-
ferent antiemetic regimens evaluating their impact on
HRQL.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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Twelve out of 13 studies are randomized, and 9 of them
were double-blind.
The first randomized double-blind study comparing dif-
ferent antiemetic prophylactic treatments that evaluated
the impact on quality of life was carried out on breast can-
cer patients submitted to the first cycle of a cyclophospha-
mide-containing regimen [17]. Ondansetron (8 mg i.v.
followed by 8 mg oral dosing three times daily for 5 days)
was compared to metoclopramide (60 mg i.v. followed by
20 mg oral dosing three times daily for 5 days) during 6
cycles of chemotherapy. Both antiemetics were combined
to a 16 mg single dose i.v. of dexamethasone before chem-
otherapy. Nausea and vomiting were recorded daily on a
diary card while quality of life was assessed before each
chemotherapy treatment and at the end of each 5-day
treatment period using the Rotterdam Symptom Checklist
questionnaire [18]. This includes 38 items summarized in
three subscales (physical, psychological and functional
activity). Each item of the physical and psychological sub-
scales is rated on a four-point scale (0 = not at all, 1 = a
little, 2 = somewhat, 3 = very much) as well as the items
related to functional activity (0 = unable, 1 = only with
help, 2 = without help, with difficulty, 3 = without help).
A separate analysis was performed for the psychological,
physical and functional activity subscales. The "lack of
sexual interest" and ability to "go to work" questions were
excluded from the analyses since > 5% of patients failed to
complete them.
Due to much missing data, the mean and not the total of
each subscale was considered. The study showed that at
the first cycle of chemotherapy ondansetron plus dexam-
ethasone was significantly superior to metoclopramide
plus dexamethasone (complete protection from vomiting
over the 5-day treatment period in 81% and 48% of
patients, respectively). Furthermore, ondansetron
induced a statistically significant improvement in the psy-
chological subscale scores with respect to metoclopra-
mide. No differences were observed in the physical and
functional activity subscales. Interestingly, patients' psy-
chological distress was stronger before chemotherapy
than after. This was probably due to the apprehension in
receiving chemotherapy for the first time. Instead, physi-
cal parameters worsened to the same degree after chemo-
therapy reflecting associated side effects. During the 6
cycles of chemotherapy 67% of patients receiving
ondansetron and 28% of patients receiving metoclopra-
Table 2: Studies comparing the impact of different antiemetics on HRQL
Author (study) [ref.] Pts (no.) Cancer 
(type)
Chemotherapy 
(emetogenicity)
Antiemetics HRQL assessment (times) Selection of pts
Soukop (DB) [17] 184 Breast Moderately DEX + OND vs DEX + MTC RSCL (before and after 6 
days)
187 pts eligible, 184 
evaluated HRQL, 2 
questions excluded (> 5% of 
pts no response)
Clavel (DB) [19] 252 Breast Moderately (FAC, 
FEC)
OND vs ALI FLIC, FLIE (before and 
after 4 days)
259 pts eligible, 252 
evaluated HRQL with FLIC 
and 246 with FLIE
Crucitt (DB) [20] 113 Breast LNH Moderately OND vs PCP FLIC, FLIE (before and 
after 4 days)
133 pts eligible, 113 
evaluable for efficacy, 57 
evaluated HRQL
Lofters (DB) [21] 696 various Moderately OND ± DEX vs DOL ± DEX EORTC QLQ-C30 (before 
and after 4 and 8 days)
703 pts eligible, 696 
evaluated HRQL
Pater (DB) [22] 402 various Moderately DEX + OND or DOL vs DEX 
(delayed emesis)
EORTC QLQ-C30 (before 
and after 4 and 8 days)
407 pts eligible, 402 
evaluated HRQL
Garbe (DB) [23] 90 Melan Highly (dacarbazine) TROP 5 mg vs TROP 10 mg Mood, food intake, QL 
scales (before and after 
CT)
n.s.
Barrenetxea (DB) [24] 182 Breast Moderately (FAC, 
FEC)
OND for 3 days vs 
OND+MTC vs OND 1 dose
FLIC (before and for 5 
days)
n.s.
Lebeau (DB) [25] 338 various Highly (cisplatin) OND+MP vs OND+MP+ 
MTP
FLIC, FLIE (before and 
after 4 days)
n.s.
Kobayashi (DB) [26] 141 various Highly (cisplatin) TROP vs PL (delayed emesis) QOL-EVJ (before and daily 
for 30 days after)
146 pts enrolled, 141 
eligible, 98 evaluated HRQL
Sorbe (R, O) [28] 259 various Highly (cisplatin) TROP vs MTC + DEX + LOR 23 items (before and after 
7 days)
n.s.
Drechsler (R, O) [29] 191 various Highly and 
Moderately
TROP vs TROP+DEX vs 
TROP+MTC
new scale (before and after 
CT)
n.s.
Torok (R, O) [30] 130 Ovary Highly (cisplatin) OND vs GRAN vs MTC RSCL (before and daily for 
5 days)
n.s.
Lachaine (O) [31] 52 Breast Moderately OND or MTC physician 
choice
EORTC QLQ-C30 (before 
and after 2 and 4 days)
58 pts eligible, 52 evaluated 
HRQL
ALI: alizapride, CT: chemotherapy, DB = Double-blind, DEX: dexamethasone, GRAN: granisetron, HRQL: Health-related quality of life, Melan: 
melanoma, MTC: metoclopramide, MTP: metopimazine O: open, OND: ondansetron, PCP: prochlorperazine, PL: placebo, R: randomized, TROP: 
tropisetron, 5-HT3: 5-HT3 antagonist, n.s.: not specifiedHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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mide had less than 3 emetic episodes. Over the 6 cycles
quality of life results revealed a more pronounced differ-
ence in favour of ondansetron in the psychological sub-
scale score as well as trends in favour of ondansetron in
the physical and functional activity subscales. Unfortu-
nately, quality of life data were not available for all
patients for all 6 cycles; therefore, a possible selection bias
favouring ondansetron cannot be excluded, especially
considering that the analysis of the 6 cycles refers to 475
assessments of ondansetron-treated patients and 380
assessments of metoclopramide-treated patients.
Another randomized, double-blind study evaluating the
impact of CIE on HRQL compared oral ondansetron (8
mg every 8–12 hours for 3–5 days starting 2 hours before
chemotherapy) with alizapride (150 mg i.v. followed by
50 mg orally administered every 8–12 hours for 3–5 days
starting 2 hours before moderately-highly emetogenic
chemotherapy) [19]. Nausea and vomiting episodes were
recorded on a diary card, while quality of life was assessed
using the FLIC and the FLIE questionnaires filled out by
the patients before chemotherapy and 4 days after. The
total score for each questionnaire was obtained by calcu-
lating the average score for each item. Complete control of
acute (57% versus 31%) and delayed (62% versus 48%)
emesis was significantly superior in the ondansetron
group than in alizapride group. Both groups experienced
deterioration in FLIC and FLIE score from pretreatment to
day 4. No difference in quality of life scores was shown
between the ondansetron and alizapride groups when
quality of life was measured by the FLIC, but when quality
of life was measured by the FLIE, ondansetron was found
superior to alizapride in preventing a decrease in quality
of life following chemotherapy (mean difference in the
scores for each question was 1.45 with ondansetron and
1.93 with alizapride, P < 0.04).
The third double-blind randomized study compared
ondansetron (8 mg orally b.i.d. for 3 days) with prochlo-
rperazine (10 mg orally b.i.d. for 3 days) in breast cancer
and lymphoma patients submitted to moderately eme-
togenic chemotherapy [20]. Patients completed the FLIC
and FLIE questionnaires before and at the end of the 3-day
study period (day 4). Total scores were transformed to
standardized scores so that the highest possible score on
either scale equated to 100. Ondansetron was signifi-
cantly superior to prochlorperazine in the complete con-
trol of emesis during the three days (60% versus 21%).
Quality of life was evaluated in only 57 of 133 patients
(34 receiving ondansetron and 23 prochlorperzine). Base-
line scores of the FLIE did not differ between groups.
Vomiting subscale scores were significantly different
between groups (from 97.1 pre to 89.2 post treatment
with ondansetron and from 96.7 pre to 70.4 post with
prochlorperazine, P < 0.01). No significant difference was
seen for the nausea subscale scores. There were no signifi-
cant differences between groups in FLIC scores at baseline
or at the end of the 3-day study period.
In two randomized double-blind studies quality of life
was evaluated with the EORTC QLQ-C30. In the first [21],
carried out in patients submitted to moderately
emetogenic chemotherapy, the efficacy of dolasetron and
ondansetron on day 1 and on day 1–7 was compared as
well as the efficacy of the addition of dexamethasone to
both. In the first 24 hours dolasetron was significantly less
effective than ondansetron but no difference was shown
between the two drugs over 7 days. The addition of dex-
amethasone significantly improved the efficacy of both
drugs during the entire period.
There were no statistically significant differences between
ondansetron and dolasetron at baseline for any of the
HRQL domains assessed. Post-treatment, there were no
significant changes in global quality of life or other
domains, except for diarrhoea (more common with dola-
setron) and constipation (more common with ondanset-
ron). Dexamethasone-treated patients fared significantly
better with respect to global quality of life, physical func-
tioning and social functioning and nausea, anorexia, diar-
rhoea, fatigue and pain.
In the second study [22] the efficacy of 5-HT3 antagonists,
ondansetron or dolasetron added to dexametasone versus
dexamethasone alone in the prevention of delayed emesis
induced by moderately emetogenic chemotherapy was
evaluated. Patients received in the first 24 hours a combi-
nation of a 5-HT3 receptor antagonist plus dexametha-
sone. The continuation of the 5-HT3 receptor antagonist
improved slightly but not significantly, the complete con-
trol of delayed emesis (47% versus 41%). Minimal differ-
ences in quality of life were observed. Social functioning
deteriorated significantly more in patients treated with
dexamethasone alone than in those receiving the combi-
nation (-6.0 points versus -0.8 points in the combina-
tion). On the other hand, patients taking 5-HT3 receptor
antagonists reported a significantly greater increase in
constipation (+26 points versus +13 points). Unfortu-
nately, there is no method for weighting the sub-compo-
nents of the QLQ-C30 with respect to their overall
importance and, therefore, to balance symptomatic
changes in one direction against functional changes in
another.
A randomised double-blind study was carried out in
advanced malignant melanoma patients submitted to
dacarbazine administered in 1, 5 or 10 days, evaluating
HRQL by unidimensional linear scales [23]. Two different
doses of tropisetron were compared: 5 and 10 mg iv.
Patients evaluated their mood, food intake and quality ofHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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life by recording scores in a diary card every day from the
day before chemotherapy until the end of the cycle. The
scores ranged from 0 (very bad) to 8 (very good). The two
dosages of tropisetron prevented vomiting in 93% and
98% of patients with 5 mg and 10 mg, respectively.
Their well being was maintained during the cycle of chem-
otherapy; in fact, mood and quality of life of the patients
remained good as well as food intake.
In another study the efficacy of three antiemetic regimens
(ondansetron 8 mg i.v. followed by 8 mg orally every 8
hours for 3 days vs ondansetron as above plus metoclo-
pramide 10 mg every 8 hours for 3 days vs ondansetron 8
mg i.v. single dose) in breast cancer patients submitted to
CMF or FEC chemotherapy was evaluated [24].
Quality of life impact was assessed by FLIC questionnaires
completed by the patients during a 5-day period following
chemotherapy. Chemotherapy cycles, and not patients,
were considered as a statistical unit. Responses were eval-
uated in 182 cycles: in 116 cycles patients received CMF
and in 66 FEC. The high-dose ondansetron regimen was
similar (CMF-treated patients) or superior (FEC-treated
patients) to the combination of ondansetron plus meto-
clopramide and always superior to the single dose of
ondansetron. Quality of life was always worse with
ondansetron single dose i.v. while no differences were
shown between ondansetron for three days versus
ondansetron plus metoclopramide.
A double-blind multicentre study evaluated two
antiemetic regimens, in patients with vomiting or moder-
ate to severe nausea in the previous cycle of cisplatin
based chemotherapy despite antiemetic treatment with a
combination of a 5-HT3 antagonist plus a corticosteroid:
ondansetron plus methylprednisolone versus ondanset-
ron plus methylprednisolone plus metopimazine [25].
The impact on the patient's quality of life was assessed
using the FLIC and the FLIE that were joined together in a
single questionnaire. This questionnaire consisted of 28
items (all 22 of the FLIC and 6 of the FLIE) and was filled
out by the patient prior to the start of chemotherapy and
at the end of the third day of antiemetic treatment.
Complete protection from vomiting throughout the cycle
of chemotherapy was achieved more frequently by
patients receiving the triple combination (53% versus
38%, P < 0.008).
Modification in quality of life (FLIC questionnaire) was
similar between the two treatment groups. The FLIE
showed a decrease in quality of life that was inferior albeit
not significantly with the triple combination.
In another double-blind study the role of tropisetron in
the prevention of cisplatin-induced delayed emesis was
evaluated. On the first day all patients received 5 mg oral
tropisetron and then were randomly assigned to receive
either tropisetron or placebo on days 2 through 5 [26]. A
newly developed quality of life questionnaire was
employed that consisted of seven scales: physical scale,
mental and related symptom scale, respiratory condition
related scale, social scale, an active scale, a scale for the
influence of nausea and vomiting on patient's daily life,
and a global scale [27]. This questionnaire was printed in
diary form and filled out every morning.
The rate of complete protection from delayed emesis in
the tropisetron group and placebo group was respectively
46.3% and 36.5%.
All scales, except social well being, changed immediately
in both groups and reached a nadir on days 2–3, after that
returning to the control levels during the two weeks after
cisplatin administration. Tropisetron treated patients
showed significantly better physical wellbeing, mental
wellbeing, functional wellbeing and global quality of life
scores with respect to placebo-treated patients.
Finally two open, randomized, multicenter studies have
been published [28,29]. The first compared tropisetron (5
mg i.v. on day 1 followed by 5 mg oral every day on days
2–6) with a metoclopramide-cocktail (metoclopramide 3
mg/kg i.v. plus dexamethasone 20 mg i.v. plus lorazepam
1 mg oral on day 1 followed by metoclopramide 10 mg
orally or 20 mg as suppositories three times a day on days
2–6) in patients submitted to consecutive cycles of cispla-
tin chemotherapy [28]. Nausea and vomiting were
recorded on a diary card while quality of life was assessed
by a non-validated questionnaire consisting of 18 ques-
tions about various symptoms and 5 questions about
appetite and social life.
On day 1 of the first cycle complete control of vomiting
was not significantly different (63% with tropisetron ver-
sus 64% with metoclopramide cocktail) while complete
control of nausea was significantly superior with the cock-
tail (40% versus 61%). The rate of complete control of
vomiting and nausea increased from day 1 to day 6 with
both antiemetic regimens, and this also happened at the
second cycle. Before both cisplatin cycles, the two groups
did not differ in the responses to the 23 questions. In post-
treatment evaluations in both treatment groups, the
patients reported more nausea, vomiting, being ill, being
tired or sleepy, and having more problems with eating
than was reported in the pretreatment evaluation. Patients
receiving tropisetron experienced significantly more con-
stipation and headache than did those treated with the
metoclopramide cocktail.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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Another open, randomized, multicentre study compared
tropisetron (5 mg i.v. day 1 and 2 followed by 10 mg
orally until two days after the end of chemotherapy) with
tropisetron (as above) plus dexamethasone (20 mg i.v. on
day 1 and 2 followed by 4 mg i.v. or orally until two days
after the end of chemotherapy) and with tropisetron (as
above) plus metoclopramide (20 mg i.v. plus 10 mg orally
b.i.d on day 1 followed by 10 mg t.i.d. orally until two
days after the end of chemotherapy) in patients submitted
to highly and moderately emetogenic chemotherapy [29].
Quality of life in this study was documented using a newly
developed, validated but not yet published, colour scale.
Tropisetron plus dexamethasone was significantly supe-
rior to tropisetron alone and tropisetron plus metoclopra-
mide for both acute and delayed emesis. Quality of life
was rated as "very good", or "good" by more than half the
patients before starting therapy. The assessment after the
first chemotherapy cycle did not reveal any general deteri-
oration. No statistical difference was detectable between
the groups; altogether 41% of the patients reported an
improvement in their quality of life after the first cycle,
while 33% stated their quality of life was unchanged and
33% deteriorated.
In these last two studies no data were reported in the
paper either on the number of patients evaluated for qual-
ity of life or on the missing values. Considering that the
evaluation is carried out in open studies the risk of selec-
tion bias and confounding is high.
Another open study compared in cisplatin-treated ovarian
cancer patients the antiemetic efficacy of ondansetron,
granisetron, and metoclopramide.
Quality of life was assessed before chemotherapy, on day
1 and during 5 days (every evening) using the Rotterdam
Symptom Checklist. In the first cycle 85% of patients
receiving ondansetron, 83% of those receiving granisetron
and 60% of those receiving metoclopramide achieved
complete protection from vomiting [30].
A statistically significant improvement in the psychologi-
cal subscale scores after ondansetron and granisetron was
observed with respect to metoclopramide. No differences
were reported in the physical activity subscale.
In an open non-randomised study, breast cancer patients
submitted to moderately emetogenic chemotherapy
received an antiemetic prophylaxis based on ondansetron
or metoclopramide. The selection of the regimen was left
to the attending physician and represented current prac-
tice at the institution [31]. Complete control of acute eme-
sis was 77% with ondansetron and 32% with
metoclopramide in the first 24 hours and 83% and 55%
on days 2–5, respectively.
With both antiemetic regimens the levels of quality of life
1 day after chemotherapy, assessed with the EORTC QLQ-
C30, were lower than prior to chemotherapy on all five
functional scales, except the emotional scale. On average,
patients who received ondansetron had a better score on
day 1 than prior to chemotherapy on this scale. The differ-
ences between groups were not statistically significant on
any of the functional scales.
Global quality of life decreased more with metoclopra-
mide than with ondansetron, but the difference was not
statistically significant (-24 versus -17).
On day 3 all scores, except the emotional dimension, were
lower than prior chemotherapy. Changes in scores on glo-
bal quality of life were similar for both groups. For the
role functioning scale, changes in scores were significantly
better for ondansetron.
Conclusions
In spite of the fact that the impact of chemotherapy-
induced nausea and vomiting on HRQL has a short-term
effect, its evaluation can be useful for clinical decisions
concerning the choice of antiemetic prophylaxis. Only the
results of antiemetic randomized clinical trials can be
used to reach this aim. Moreover, because of the subjectiv-
ity of the patient's answers, only a double-blind study can
assure reliable results. Finally, only the correct choice of
the antiemetic treatments to be compared can lead to use-
ful results [32]. In fact, if the new antiemetic prophylaxis
were compared to a treatment different from the best, no
information about the differences between the mean
scores of the two arms (new treatment and standard ther-
apy) would be available. More precisely, the above men-
tioned difference could be due only to an inferior efficacy
of the used comparator with respect to the standard
antiemetic therapy. For similar reasons any comparison
involving sub optimal antiemetic regimens could be
regarded as useless for a specific clinical decision.
Only 9 out of 13 comparative studies identified in our
research were randomized and double-blind; three of
them were concerned with non-standard antiemetic ther-
apies, and two were dose finding studies. Therefore, only
the results of 4 studies can be regarded as useful for orient-
ing the choice of an antiemetic prophylaxis.
Summarizing the results obtained by the comparative
studies carried out until now, the efficacy, tolerability and
impact on HRQL of antiemetic regimens containing 5-
HT3 receptor antagonists were found superior to those
that referred to the earlier used antiemetic drugs (metoclo-
pramide, alizapride and prochlorperazine). Furthermore,
in one study the combination of ondansetron plus dex-
amethasone, still the standard treatment for theHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/46
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prevention of acute emesis induced by moderately eme-
togenic chemotherapy, was evaluated against metoclopra-
mide plus dexamethasone. Its results show that the first
antiemetic prophylaxis, allowing a better control of nau-
sea and vomiting during the first 24 hours, also lead to an
improvement in the patients HRQL.
Among the 13 comparative studies, a great heterogeneity
of instruments aimed at evaluating HRQL was detected: in
4 studies FLIC and/or FLIE, in 3 the EORTC QLQ-C30, in
2 the Rotterdam Symptom Checklist, in 2 a uniscale, in 2
an ad hoc designed instrument was used. The reasons of
the choice of the instrument to use to assess the influence
of emesis on HRQL are clearly described by Uyl-deGroot
et al. [32].
In conclusion, even if the number of the published studies
specifically aimed to evaluate the impact of the chemo-
therapy-induced emesis on HRQL can be considered suf-
ficiently high, those showing results that are reliable and
useful to orient the clinical decision are few. Also consid-
ering the improvement in antiemetic therapy obtained in
the last few years, and the more frequent implementation
of reliable antiemetic guidelines, as well as the recent
increasing diffusion of lower emetogenic chemotherapies,
more research should be performed to obtain results on
the impact of CIE on HRQL useful to orient the choice of
antiemetic therapy.
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